Reuters logo
BRIEF-Amphion's partner company announces positive topline results for iclaprim in REVIVE-2 Phase 3 study
October 5, 2017 / 6:24 AM / 16 days ago

BRIEF-Amphion's partner company announces positive topline results for iclaprim in REVIVE-2 Phase 3 study

Oct 5 (Reuters) - AMPHION INNOVATIONS PLC:

* PARTNER COMPANY RELEASES POSITIVE CLINICAL RESULTS

* SAYS ‍ICLAPRIM MET PRIMARY ENDPOINT​

* SAYS ‍ICLAPRIM WAS WELL TOLERATED IN STUDY​

* SAYS ‍NDA SUBMISSION EXPECTED IN Q1 OF 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below